Asieris Received NMPA IND Approval for a Novel USP1 Inhibitor for the Treatment of Advanced Solid Tumors
January 16, 2025 Asieris Received NMPA IND Approval for a Novel USP1 Inhibitor for the Treatment of Advanced Solid Tumors
January 6, 2025 Asieris and CDC Sign Investigational Product Supply Agreement for APL-1202 in Free-Living Amoeba Infections Treatment under Expanded Access Investigational New Drug Program
November 12, 2024 Asieris Unveils Results for the First Time at 2024 IPVC the Analysis of the of HPV Clearance Rate for Different HPV Types and Different Follow-up Times of the Non-Surgical Treatment for Cervical HSIL Product APL-1702 Clinical Study